Citius Pharmaceuticals financials
$0.5545+1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 | FY20 Sep 30 | FY19 Sep 30 | FY18 Sep 30 | FY17 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M | -$17.7M | -$15.6M | -$13.8M | -$10.0M |
| Net income | -$37.4M | -$40.2M | -$33.7M | -$33.6M | -$24.5M | -$17.5M | -$15.6M | -$12.5M | -$10.4M |
| Net margin | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-3.38 | $-5.97 | $-5.57 | $-5.75 | $-5.75 | $-11.25 | $-19.25 | $-29.25 | $-47.25 |
| EBITDA | -$38.5M | -$42.0M | -$36.7M | -$33.1M | -$23.4M | -$17.6M | -$15.6M | -$13.8M | -$10.0M |
| Operating cash flow | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M | -$16.9M | -$12.4M | -$11.3M | -$8.0M |
| Free cash flow | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$64.3M | -$16.9M | -$12.4M | -$11.3M | -$8.0M |
| Diluted shares | 11.1M | 6.7M | 6.1M | 5.8M | 4.3M | 1.6M | 0.8M | 0.4M | 0.2M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M | $13.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $427.5K |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M | $43.8M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M | $10.1M |
| Shareholders' equity | $77.5M | $74.1M | $91.4M | $103.4M | $132.8M | $33.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology